137 completed, 40 recruiting, 27 terminated, 24 active not recruiting. 269 Phase 2, 70 Phase 1, 5 Phase 3.
Follow Neuroblastoma: new trials by email Literature Review of Neuroblastoma trials Research Report on Neuroblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab Radiation: 131I-MIBG, Dinutuximab, Vorinostat - Neuroblastoma | Phase 2 | Not yet recruiting | New Approaches to Neuroblastoma Therapy Consortium | 118 | 2026-12-31 | 2026-08-21 |
| 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma GD2, PSMA and CD276 CAR-T cells - Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2026-12-31 | 2026-10-30 |
| Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma CIML-NK Cells - Neuroblastoma | Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 20 | 2026-12-01 | 2026-08-24 |
| A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma Zanzalintinib - Metastatic Olfactory Neuroblastoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 16 | 2026-10-01 | 2026-10-05 |
| Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma Biospecimen Collection, Computed Tomography, Florbenguane F18 - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 2 | Withdrawn | Children's Oncology Group | 2026-09-22 | 2026-09-16 | |
| Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 Naxitamab - High-Risk Neuroblastoma | Phase 2 | Recruiting | Shaare Zedek Medical Center | 10 | 2026-06-23 | 2026-09-17 |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas Eflornithine (DFMO), AMXT 1501 Dicaprate - Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes | Phase 1 / Phase 2 | Recruiting | Milton S. Hershey Medical Center | 265 | 2026-05-13 | 2026-09-03 |
| Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma EB-DTNB-NK, Fludarabine, Cyclophosphamide - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-03-30 |
| Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma. 18F-MFBG PET/CT imaging - Neuroblastoma | Phase 2 | Not yet recruiting | Institut Curie | 30 | 2026-03-01 | 2025-09-03 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide - Neuroblastoma (NB), Neuroblastoma in Children | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 27 | 2026-01-06 | 2026-10-01 |
| An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma anti-GD2-800CW - Neuroblastoma | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 22 | 2025-11-05 | 2026-02-10 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma Arsenic trioxide, MAPK inhibitors, Chemotherapy - Neuroblastoma | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 92 | 2025-05-01 | 2025-04-18 |
| A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma autologous NK cell plus GD2 antibody - Neuroblastoma, GD2 Antibody | Phase 1 / Phase 2 | Not yet recruiting | Guangzhou Women and Children's Medical Center | 15 | 2025-05-01 | 2025-04-29 |
| PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors PEEL-224, Vincristine, Temozolomide (TMZ) - Refractory Solid Tumors, Relapsed Solid Tumors | Phase 1 / Phase 2 | Recruiting | Theodore Laetsch | 59 | 2025-03-23 | 2026-10-06 |
| Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma Autologous hALK.CAR T cells - Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 / Phase 2 | Recruiting | Roberto Chiarle | 42 | 2025-01-31 | 2025-12-26 |
| 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System 18F-mFBG - Neuroblastoma, Pheochromocytoma | Phase 2 | Withdrawn | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | 2025-01-01 | 2025-01-21 | |
| NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Universal Donor (UD) TGFβi NK Cells, Temozolomide, Irinotecan - Neuroblastoma | Phase 2 | Recruiting | New Approaches to Neuroblastoma Therapy Consortium | 62 | 2024-12-16 | 2026-07-20 |
Showing 20 of 269. Sign in to see all of them.
Sarcoma (54) · Osteosarcoma (51) · Rhabdomyosarcoma (46) · Medulloblastoma (42) · Wilms Tumor (42) · Sarcoma, Ewing (37) · Lymphoma, Non-Hodgkin (34) · Neuroectodermal Tumors, Primitive, Peripheral (33) · Central Nervous System Neoplasms (30) · Lymphoma (26) · Burkitt Lymphoma (24) · Hepatoblastoma (24) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (24) · Recurrence (24)
Neoplasms, Glandular and Epithelial (269) · Neoplasms, Nerve Tissue (269) · Neoplasms, Neuroepithelial (268) · Neoplasms by Histologic Type (267) · Neuroectodermal Tumors (267) · Neoplasms, Germ Cell and Embryonal (266) · Neuroectodermal Tumors, Primitive (264) · Neoplasms (248) · Neuroectodermal Tumors, Primitive, Peripheral (236) · Neoplasms by Site (103) · Neoplasms, Connective and Soft Tissue (88) · Nervous System Diseases (72) · Neoplasms, Connective Tissue (65) · Female Urogenital Diseases (61) · Female Urogenital Diseases and Pregnancy Complications (61)
Cyclophosphamide (44) · Etoposide (31) · Temozolomide (28) · Carboplatin (26) · Irinotecan (25) · Isotretinoin (23) · Doxorubicin (22) · Filgrastim (22) · Topotecan (22) · Vincristine (22) · Melphalan (20) · Cisplatin (19) · Radiotherapy (19) · sargramostim (19) · dinutuximab (18)
National Cancer Institute (NCI) (35) · Memorial Sloan Kettering Cancer Center (26) · Children's Oncology Group (18) · Giselle Sholler (9) · St. Jude Children's Research Hospital (8) · Fred Hutchinson Cancer Center (7) · Children's Cancer and Leukaemia Group (6) · M.D. Anderson Cancer Center (5) · New Approaches to Neuroblastoma Therapy Consortium (5) · Dana-Farber Cancer Institute (4) · European Infant Neuroblastoma Study Group - 1999 (4) · Nationwide Children's Hospital (4) · Samsung Medical Center (4) · Sue O'Dorisio (4) · Y-mAbs Therapeutics (4)
United States (194) · Canada (40) · France (26) · United Kingdom (25) · Australia (21) · Spain (21) · Puerto Rico (19) · Italy (18) · Germany (17) · China (13) · Switzerland (13) · Austria (10) · Belgium (10) · Denmark (10) · Netherlands (10)
Brian Kushner, MD (9) · Brian H. Kushner, MD (5) · Giselle Sholler, MD (5) · Nai-Kong V. Cheung, MD, PhD (5) · Yizhuo Zhang (4) · Katherine K. Matthay, MD (3) · Bruno De Bernardi, MD (2) · Charalampos Floudas, M.D. (2) · Frank Berthold, MD (2) · Gregory Yanik, MD (2) · Henry S. Friedman, MD (2) · Herve Rubie, MD (2) · Jean Marie Michon, MD (2) · John M. Maris, MD (2)
PMID 31401903, PMID 23633099, PMID 38917371, PMID 11857322, PMID 11904735, PMID 14767498, PMID 15337804, PMID 16532433, PMID 16826357, PMID 17114659, PMID 17369569, PMID 17545536, PMID 17610262, PMID 19171715, PMID 19533657, PMID 19841031, PMID 20921469, PMID 20935224, PMID 20943374, PMID 21115869, PMID 21172879, PMID 21791630, PMID 22203761, PMID 22665539, PMID 23598171, PMID 24520094, PMID 25965900, PMID 26062933, PMID 26611425, PMID 26742708, PMID 26773712, PMID 27465021, PMID 28032129, PMID 28111925, PMID 28153957, PMID 28549783, PMID 29147617, PMID 29181270, PMID 30093449, PMID 30326045, PMID 30777875, PMID 30850872, PMID 31595663, PMID 31838007, PMID 32127657, PMID 32192573, PMID 32221013, PMID 32343642, PMID 32391579, PMID 32506485
U10CA180886 (20), U10CA098543 (12), 2023 (4), P30CA006516 (3), R01CA167632 (3), UM1CA097452 (3), 2009 (2), P30CA008748 (2), UM1CA228823 (2), 2014 (1), 2017 (1), 2018 (1), 2019 (1), N01CM62202 (1), P01CA081403 (1)